Whyte et al. (15) evaluated the impact of acetylcholinesterase inhibitors on cognitive and functional recovery in an open-label pilot study of stroke patients over 60 years old with post-stroke cognitive decline (excluding individuals with prior Alzheimer’s disease). This evidence concerns the gene ACHE and stroke disorder.